# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(0.46) per share. This is a 98.77 percent increase over losses of $(37.31) p...
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innov...
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune dise...